Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN

Core Viewpoint - Kahn Swick & Foti, LLC is investigating the proposed sale of Day One Biopharmaceuticals, Inc. to Servier, focusing on the adequacy of the sale price of $21.50 per share and the process leading to this valuation [1]. Group 1: Proposed Sale Details - The proposed transaction involves Day One Biopharmaceuticals, Inc. shareholders receiving $21.50 in cash for each share they own [1]. - KSF is assessing whether the proposed consideration adequately reflects the company's value or if it undervalues the company [1]. Group 2: Legal Rights and Contact Information - Shareholders who believe the transaction undervalues the company can discuss their legal rights with KSF without obligation or cost [1]. - Interested parties can contact KSF Managing Partner Lewis S. Kahn via email or phone for more information [1].